

1 **Long-Term Outcomes After Transcatheter Aortic Valve Replacement: Meta-Analysis of**  
2 **Kaplan-Meier-Derived Individual Patient Data**

3

4 Junichi Shimamura, MD <sup>a</sup>, Sho Takemoto, MD <sup>b</sup>, Shinichi Fukuhara, MD<sup>c</sup>, Yoshihisa  
5 Miyamoto, MD <sup>d</sup>, Yujiro Yokoyama, MD <sup>e</sup>, Hisato Takagi, MD, PhD <sup>f</sup>, Polydoros N  
6 Kampaktsis, MD<sup>g</sup>, Dhaval Kolte MD, PhD<sup>h</sup>, Kendra J Grubb, MD, MHA <sup>a</sup>, and Toshiki Kuno,  
7 MD, PhD <sup>i#</sup>, Azeem Latib MD <sup>i#</sup>

8 <sup>a</sup> Division of Cardiothoracic Surgery, Department of Surgery, Emory University School of  
9 Medicine, Atlanta, GA

10 <sup>b</sup> Department of Cardiovascular Surgery, Kyushu University Hospital, Fukuoka, Japan

11 <sup>c</sup> Department of Cardiac Surgery, University of Michigan, Ann Arbor, MI

12 <sup>d</sup> Division of Nephrology and Endocrinology, University of Tokyo, Tokyo, Japan

13 <sup>e</sup> Department of Surgery, St. Luke's University Health Network, PA, USA

14 <sup>f</sup> Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan

15 <sup>g</sup> Division of Cardiology, Columbia University Irving Medical Center, New York City, NY

16 <sup>h</sup> Division of Cardiology, Massachusetts General Hospital and Harvard Medical School,  
17 Boston, MA

18 <sup>i</sup> Division of Cardiology, Montefiore Medical center, Albert Einstein Medical College, NY

19 # Contributed equally as co-senior authors

20

21 **Short title:** Long-Term Outcomes After TAVR: Meta-Analysis

22

23 **Address correspondence to**

24 Shinichi Fukuhara, MD, Department of Cardiac Surgery, University of Michigan.

25 1500 E Medical Center Dr, Ann Arbor, MI 48109. Email: [fukuhara@med.umich.edu](mailto:fukuhara@med.umich.edu)

26 Toshiki Kuno, MD, PhD, Division of Cardiology, Montefiore Medical Center, Albert Einstein

27 College of Medicine. 111 East 210th St, New York, NY 10467–2401

28 E-mail: [tkuno@montefiore.org](mailto:tkuno@montefiore.org) +1-718-920-2057

29 \*Drs Kuno and Fukuhara contributed equally as co-senior authors

30

31 Total Word count: 4300

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51 **Glossary of Abbreviations**

52 SAVR surgical aortic valve replacement

53 STS the Society of Thoracic Surgeons

54 SVD structural valve deterioration

55 TAVR transcatheter aortic valve replacement

56 THV transcatheter heart valve

57 PROM predicted risk of mortality

58 PPM prosthesis patient mismatch

59

60

61 **What is new?**

62 - Meta-analysis of time-to-event data was performed to assess long-term outcomes

63 following transcatheter aortic valve replacement in a large population.

64 - Six studies, including 4,910 patients with follow-up periods of more than 20 years were

65 identified and analyzed.

66 - Nearly 88% of patients who underwent transcatheter aortic valve replacement died within

67 10 years, while 85% remained free from structural valve deterioration at 8 years.

68

69 **Perspective Statement What are the clinical implications?**

70 - This meta-analysis demonstrated excellent freedom from structural valve deterioration in  
71 intermediate- to high elderly risk patients.

72 - Baseline patient characteristics correlated with high mortality at 10 years.

73 - Further investigation into the outcomes in younger and lower-risk populations is

74 imperative to evaluate the future expanded indications for transcatheter aortic valve

75 replacement.

76

77 **Abstract**

78 **Background:** Transcatheter aortic valve replacement (TAVR) is as an alternative treatment to  
79 surgical AVR, but the long-term outcomes of TAVR remain unclear. This study aimed to  
80 analyze long-term outcomes following TAVR using meta-analysis.

81 **Methods:** A literature search was performed with MEDLINE, EMBASE, Cochrane Library,  
82 Web of Science, and Google Scholar through December 2022; studies reporting clinical  
83 outcomes of TAVR with follow-up periods of  $\geq 8$  years were included. The outcomes of  
84 interest were overall survival and/or freedom from structural valve deterioration (SVD).  
85 Surgical risk was assessed with the Society of Thoracic Surgeons (STS) predicted risk of  
86 mortality (PROM) score. A subgroup analysis was conducted for intermediate-/high-surgical  
87 risk patients only.

88 **Results:** Eleven studies including 5,458 patients were identified and analyzed. The mean age  
89 was  $82.0 \pm 6.5$  years, and mean STS PROM score ranged from 2.9 to 10.6%. Survival rate at 5  
90 and 10 years was  $47.7\% \pm 1.4\%$  and  $12.1 \pm 2.0\%$ . Five studies including 1,509 patients were  
91 analyzed for SVD. Freedom from SVD at 5 and 8 years was  $95.5 \pm 0.7\%$  and  $84.9 \pm 3.1\%$ .  
92 Similar results for survival and SVD were noted in the subgroup analysis of  
93 intermediate-/high-risk patients.

94 **Conclusions:** Following TAVR, approximately 88% of patients died within 10 years, whereas  
95 85% were free from SVD at 8 years. These data suggest that baseline patient demographic have  
96 the greatest impact on survival, and SVD does not seem to have a prognostic impact in this  
97 population. Further investigations on longer-term outcomes of younger and lower-risk patients  
98 are warranted.

99 **Keyword:** Transcatheter aortic valve replacement, structural valve deterioration, aortic valve,  
100 aortic stenosis

101

## 102 **Introduction**

103 Transcatheter aortic valve replacement (TAVR) has been established as an alternative  
104 to surgical aortic valve replacement (SAVR) for most patients with severe aortic stenosis.  
105 Current practice guidelines recognize TAVR as a safe and effective option for patients across  
106 the surgical risk spectrum, for patients aged  $\geq 65$  years in the United States and  $\geq 75$  years in  
107 Europe[1, 2]. Although several randomized controlled trials have demonstrated short- and  
108 mid-term non-inferiority between the treatment with TAVR and SAVR in intermediate and  
109 low-surgical risk patients [3-5], data on long-term outcomes are still limited. Therefore,  
110 long-term durability of TAVs remains largely uncertain and there are concerns regarding the  
111 lack of data on long-term mortality and structural valve deterioration (SVD). In this context,  
112 we conducted a systematic review and meta-analysis to evaluate the long-term results beyond  
113 five years following TAVR.

114

## 115 **Methods**

116 This study complies with the Preferred Reporting Items for System and Reviews and  
117 Meta-Analysis statement standards[6]. Studies were included if the following criteria were  
118 met;

- 119 (1) The study design was randomized or nonrandomized, retrospective or prospective  
120 observational study with matched or unmatched populations;
- 121 (2) The study included patients with aortic stenosis who underwent TAVR;
- 122 (3) The study reported survival and/or incidence of SVD or freedom from SVD;
- 123 (4) Kaplan-Meier curves were available with numbers at risk present  $\geq$  eight years.

124 The included studies were not restricted to any language. The eligible studies were  
125 identified using a 2-level strategy. First, databases including MEDLINE, EMBASE,

126 Cochrane Library, Web of Science, and Google Scholar were searched through November  
127 2022 using Web-based search engines. Search terms included “transcatheter aortic valve  
128 replacement”, “transcatheter aortic valve implantation”, “transcatheter heart valve (THV)”,  
129 and “transcatheter aortic valve”. Second, relevant articles were manually identified through  
130 secondary sources, including the first identified studies’ reference lists. Two authors (ST and  
131 JS) independently reviewed extracted publications. Studies were included only if two  
132 investigators agreed. Two independent investigators (ST and JS) evaluated the risk of bias in  
133 individual studies using the Joanna Briggs Institute (JBI) critical appraisal checklist  
134 (Supplemental Table 1). The following information was extracted: authors, year of  
135 publication, year of enrollment/procedure performed, sample size, age, follow-up periods,  
136 predicted risk of mortality by the Society of Thoracic Surgeons (STS) predicted risk of  
137 mortality (PROM) score[7], New York Heart Association class III/IV heart failure and left  
138 ventricular ejection fraction at the time of TAVR, history of diabetes mellitus, hypertension,  
139 peripheral vascular disease, chronic obstructive pulmonary disease, renal failure, myocardial  
140 infarction, atrial fibrillation, and stroke, previous coronary artery bypass graft or any cardiac  
141 surgery and pacemaker implantation, type of implanted valve and approach, 30-day mortality,  
142 cardiovascular mortality, and incidence of SVD.

#### 143 *Outcomes of interest*

144 The primary outcome of this study was overall survival. The secondary outcome of  
145 interest was freedom from SVD.

#### 146 *Definition of SVD*

147 The European guidelines task force committee definition was used by all studies[8].  
148 Moderate SVD was present when any of the following was present; 1) mean trans-prosthetic  
149 gradient  $\geq 20$  mmHg and  $< 40$  mmHg; 2)  $\geq 10$  mmHg and  $< 20$  mmHg increase from  
150 baseline; 3) moderate new or worsening intra-prosthetic aortic regurgitation. Severe SVD was

151 present when any of the following was present; 1) mean trans-prosthetic gradient  $\geq 40$   
152 mmHg; 2)  $\geq 20$  mmHg increase from baseline; 3) severe new or worsening intra-prosthetic  
153 aortic regurgitation.

154

#### 155 *Statistical analysis*

156 We analyzed data from the included studies based on the approach demonstrated by  
157 Liu *et al.* to obtain a merged Kaplan-Meier curve from individual Kaplan-Meier curves[9].  
158 First, raw data coordinates (time, survival probability, or freedom from SVD) were extracted  
159 from Kaplan-Meier curves. If the incidence of moderate and severe SVD was reported  
160 separately, only moderate SVD data was included to avoid underestimating the incidence of  
161 SVD given the low incidence of severe SVD [10, 11]. Second, individual patient data in each  
162 study were reconstructed from data coordinates and the numbers at risk at given timepoint  
163 using the R package “IPDfromKM”. Finally, we merged individual patient data of all eligible  
164 studies, and drew the Kaplan-Meier curve. The analysis was conducted with R Statistical  
165 Software (version 4.2.1, Foundation for Statistical Computing, Vienna, Austria). Median  
166 values in each study were converted to mean using the quantile estimation method reported  
167 by McGrath *et al.* [12]. The converted mean data were combined into one group by  
168 Cochrane’s formula (<https://training.cochrane.org/handbook/current/chapter-06>). In addition,  
169 we also performed a subgroup analysis of patients at intermediate- or high-surgical risk.

170

## 171 **Results**

### 172 **Literature selection results**

173 A total of 11,987 studies were identified, published from 2002 to 2016, after removal  
174 of duplicates and evaluation based on the selection criteria, 12 studies were included in the  
175 meta-analysis (Figure 1). Eleven studies with a total of 5,458 patients were included in the

176 survival analysis[11, 13-22]. One study was a randomized controlled trial and remaining ten  
177 studies were observational. Five studies with 1,509 patients were included in the analysis of  
178 freedom from SVD [10, 11, 16, 17, 19]. One study was a randomized controlled trial, and  
179 remaining studies were observational. Four of these five studies were also included in the  
180 survival analysis[11, 16, 17, 19]. The included studies are summarized in Table 1. The  
181 studies were conducted between 2002 and 2016. Only one study (the NOTION trial) included  
182 145 patients with low-surgical risk (2.7% for survival analysis and 9.6% for SVD analysis of  
183 the study population).

184

### 185 **Patient and procedure characteristics**

186 Patient characteristics are summarized in Table 1. In the survival analysis, the longest  
187 follow-up ranged from 8 to 12.4 years among included studies, with a weighted median of 4.9  
188 years. Pooled mean age was  $82.0 \pm 6.5$  years, and the mean STS PROM score ranged from  
189 2.9 to 10.6%. Regarding the implantation approach, 76.5% (4,175/5,458) of cases were  
190 transfemoral TAVR. In the freedom from SVD analysis, the mean age was  $80.1 \pm 7.1$  years,  
191 and a weighted median follow-up period was 5.8 years. The longest follow-up period ranged  
192 from 8 to 11 years. Valve types are described in Table 2. In five studies reporting freedom  
193 from SVD, 722 (47.8%) TAVRs were performed using SAPIEN<sup>®</sup>, SAPIEN XT<sup>®</sup>, or SAPIEN  
194 3<sup>®</sup> valves (Edwards Lifesciences, Irvine, California, USA), and 643 (42.6%) using  
195 CoreValve<sup>®</sup> (Medtronic, Minneapolis, Minnesota, USA). Early-generation THVs (SAPIEN,  
196 SAPIEN XT, CoreValve) accounted for 90.5% of patients.

197

### 198 **All-cause mortality and freedom from SVD**

199 Survival rate and freedom from SVD in each study are summarized in Supplemental  
200 Tables 2A and 2B. Aggregated survival rate was  $47.7 \pm 1.4\%$  and  $12.1 \pm 2.0\%$  at 5 and 10



201 years, respectively (Figure 2A). Incidence rate of death was 13.8 per 100 person-years (i.e.,  
202 13.8% annually). Aggregated freedom from SVD was  $95.5 \pm 0.7\%$  and  $84.9 \pm 3.1\%$  at 5 and  
203 8 years, respectively (Figure 3A). The 11 studies in the survival analysis did not provide  
204 information on the specific causes of death; however, 6 of the 11 studies disclosed the  
205 percentages of cardiovascular death to overall death, which ranged from 7.6% to 60.5%.  
206 Timing of death, the incidence of early and late mortality, and incidence of cardiovascular  
207 death are summarized in Supplemental Table 3.

208

### 209 **Subgroup analysis of intermediate- or high-surgical risk patients**

210 In the subgroup analysis excluding the one study with low-surgical risk patients, the  
211 mean age was  $82.1 \pm 6.6$  years old, and the mean STS PROM score ranged from 4.6 to 10.6%.  
212 Survival rate at 5 and 10 years was  $47.0\% \pm 1.3\%$  and  $11.4 \pm 2.2\%$ , respectively (Figure 2B).  
213 Freedom from SVD at 5 and 8 years was  $95.5 \pm 0.7\%$  and  $85.0 \pm 3.3\%$ , respectively (Figure  
214 3B).

215

### 216 **Discussion**

217 In this meta-analysis of 11 studies (5,458 patients with an average age of 82 years and  
218 mostly high/intermediate-surgical risk), we report the following important findings: (1)  
219 overall survival following TAVR at 10 years was  $12.1 \pm 2.0\%$ ; (2) freedom from SVD at 8  
220 years was  $84.9 \pm 3.1\%$ .

221

222 Long-term survival

223 The high late mortality rate in our study was mainly attributed to the elderly  
224 population with a short life expectancy and significant comorbidities reflected in the high  
225 STS PROM scores. This data must be interpreted based on the natural history of severe aortic

226 stenosis, life expectancy of the matched population, and mortality following surgical aortic  
227 valve replacement (SAVR). If severe aortic stenosis is left untreated, the annual mortality rate  
228 of patients with untreated severe aortic stenosis is known to be approximately 25%[23]. Also,  
229 patients who did not undergo TAVR had 5-year mortality of 93.6%, which is higher than  
230 10-year mortality among patients who underwent TAVR in this study[24].

231           Regarding long-term survival following SAVR, Malvindi et al. analyzed 1,870  
232 patients aged 80 years and over with logistic EuroSCORE of 13.3 % who underwent SAVR  
233 and reported that the survival rate was 31% at 10 years, which was similar to the expected  
234 survival of a sex- and aged -matched population[25]. Similarly, in a study by Brennan et al.  
235 analyzing over 43,000 patients who underwent SAVR with either mechanical or bioprosthetic  
236 prosthesis primarily for aortic stenosis, the survival rate for high-risk patients was  
237 approximately 20% at 8 years[26]. In contrast, the NOTION trial included patients of similar  
238 age (mean age, 79) but low surgical risk and treated with self-expanding CoreValve, and the  
239 survival rate was higher with 51.8% at 8 years following TAVR[17]. Given the small number  
240 of patients in NOTION in our study, the survival rate was similar with or without low  
241 surgical-risk patients included, resulting in mostly intermediate-high risk patients with a  
242 higher mortality rate. Nonetheless, to understand the accurate survival of elderly patients  
243 undergoing TAVR with low-/intermediate-risk, especially over 75 years of age, a further  
244 analysis based on the surgical risk stratification is warranted. Moreover, since the cut-off age  
245 for TAVR is still controversial and there exists a difference between the two major  
246 guidelines[1, 2], understanding the long-term survival data in younger patients, such as those  
247 between 65-75 years of age, is essential before expanding the indication for TAVR.

248           Prosthesis-patient mismatch (PPM) is another important consideration. Despite  
249 technological advances in valve design, PPM is an unsolved complication following SAVR

250 and TAVR. Although the impact of post-SAVR PPM on survival has been well-recognized,  
251 the evidence regarding post-TAVR PPM remains limited[27] with some data that PPM may  
252 influence the survival following TAVR[28]. The incidence of PPM appears higher with  
253 balloon-expandable valve than self-expandable valve, whereas the impact on survival seems  
254 to be higher with self-expandable valve than balloon-expandable valves[29, 30]. Further  
255 assessment of PPM incidence and its prognostic significance stratified by valve type are  
256 needed.

## 257 Freedom from SVD

258 Our meta-analysis of SVD at 8-year provides insights into long-term THV  
259 performance. Studies reporting durability of the THVs according to the new standardized  
260 criteria of the 2017 EAPCI/ESC/EACTS consensus, moderate SVD was reported at  
261 3.6-14.9%, severe at 0.8-3.7% at follow-up of 5-8 years[10, 11, 16, 17, 19].

262 Due to the extremely low late survival and the resultant influence on the SVD rate as  
263 competing events, our results should be interpreted with caution. Nevertheless, we  
264 demonstrate acceptable durability of TAVR at 8 years with over 85% of patients were free  
265 from SVD. We elected to use the 2017 consensus document definition of SVD as it better  
266 corresponded with the era of the trials included in this meta-analysis. The Valve Academic  
267 Research Consortium 3 definitions were published subsequently and may provide a more  
268 consistent definition of SVD going forward[31].

269 A main clinical concern currently is whether TAVR valves show non-inferior durability  
270 compared to bioprosthetic SAVR valves. The frequency of SVD based on reintervention of  
271 the Carpentier-Edward PERIMOUNT aortic valve at 10 and 20 years were 1.9% and 15%  
272 overall[32] in a study of 12,569 patients (mean age,71). Few randomized trials have  
273 compared long-term durability of TAVR valves vs bioprosthetic SAVR and results are  
274 conflicting. In NOTION trial, 280 patients (mean age, 79.1) with low surgical risk were

275 randomized. At 8 years of follow-up SVD was lower in TAVR than SAVR (13.9% vs 28.3%).  
276 In the post hoc analysis of pooled data from the CoreValve US High Risk Pivotal and  
277 SURTAVI trials, a total of 2,099 patients (mean age, 82.1) were included. At 5 years of  
278 follow-up, cumulative incidence of SVD treating death as a competing risk was lower in  
279 patients undergoing TAVR than SAVR (TAVR, 2.2%; SAVR 4.38%). SVD was associated  
280 with a two-fold increased risk of 5-year all-cause mortality[32]. Ueyama et al. performed a  
281 network meta-analysis to compare the durability of the THVs (balloon-expandable and  
282 self-expandable) and SAVR prosthesis[33]. They reported that self-expandable valves  
283 demonstrated significantly larger effective orifice area, lower mean aortic valve gradient, and  
284 lower incidence of SVD compared with balloon-expandable and SAVR valves at 5 years.  
285 Both TAVR valves suffered an increased risk of aortic regurgitation and re-intervention  
286 compared with SAVR valves. The latest generation bioprosthesis for SAVR, the INSPIRIS  
287 RESILIA<sup>®</sup> aortic valve (Edwards Lifesciences LLC, Irvine, CA) using calcification-prevent  
288 technology, has demonstrated 100% of freedom from SVD in 689 patients at 5 years,  
289 expecting further longer-term durability[34]. Similarly, SAPIEN 3 Ultra RESILIA which  
290 has been recently launched has enhanced calcium blocking properties and future THVs also  
291 may be able to provide better durability with technological advances. For the accurate  
292 understanding of the THV durability, even longer follow-up, assessment stratified by valve  
293 type and generation, and echocardiographic data are essential.

294 In our study, both balloon-expandable valve and self-expandable valves were used  
295 (only balloon-expandable in two, only self-expandable in one, and both valves in two studies).  
296 A comparative study between CoreValve and SAPIEN up to 7 years was performed by  
297 Deutsch et al., demonstrated favorable outcomes in SVD with CoreValve[35]. (11.8% in  
298 CoreValve vs 22.6% in SAPIEN). This result may be explained by supra-annular  
299 configuration of self-expandable valves, which provides a larger effective orifice area than

300 balloon-expandable valves with intra-annular leaflet design. Devices of different generations  
301 were also included in our study. Early-generation THVs (SAPIEN, SAPIEN XT, CoreValve)  
302 accounted for 90.5% of patients in the current SVD analysis. Further study is warranted  
303 regarding the incidence of SVD in patients treated with newer generation valves and  
304 performance of each THVs should be assessed individually.

305

### 306 *Limitations*

307 This study has several limitations. First, our study included only one randomized study  
308 and has the inherent limitations of meta-analysis related to the retrospective observational  
309 studies. Therefore, we could only perform a single arm analysis of patients underwent TAVR.  
310 Second, follow-up on valve durability was performed in a survival cohort with death exerting  
311 a competing risk and it may have biased and underestimated the SVD rate. Third, as in all  
312 studies with long-term follow-up, patient cohort and utilized THVs (type or generation) and  
313 approaches differ from the current population and technologies. Causes of death were not  
314 available in most of the studies, resulting in the difficulty to assess the impact of  
315 cardiovascular events on mortality.

316

### 317 **Conclusions**

318 Among elderly TAVR recipients in the intermediate- to high-risk category, approximately  
319 88% died within 10 years, which is markedly superior compared to the untreated severe AS  
320 population. Over 85% of patients were free from SVD at eight years, suggesting acceptable  
321 durability of the early generation TAVR valves. Further longer-term investigations in  
322 younger and lower-risk patients with newer generation TAVR valves are warranted.

323

324

325

326 **Funding:** None

327 **Disclosure:** Dr. Fukuhara serves as a consultant for Terumo Aortic, Artivion, and Medtronic

328 Inc. Dr. Grubb serves as a consultant or receives an honorarium from Medtronic, Abbott,

329 Boston Scientific, 4C Medical, Ancora, and educational funding from Edwards Lifesciences,

330 Dr Latib is a consultant and/or has served on the advisory board of Medtronic, Boston

331 Scientific, Edwards Lifesciences, Abbott, and Anteris.

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351 **Reference**

352

- 353 1. Otto, C.M., et al., *2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart*  
354 *Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee*  
355 *on Clinical Practice Guidelines*. Circulation, 2021. **143**(5): p. e72-e227.
- 356 2. Vahanian, A., et al., *2021 ESC/EACTS Guidelines for the management of valvular heart disease:*  
357 *Developed by the Task Force for the management of valvular heart disease of the European Society of*  
358 *Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)*. Rev Esp Cardiol  
359 (Engl Ed), 2022. **75**(6): p. 524.
- 360 3. Leon, M.B., et al., *Outcomes 2 Years After Transcatheter Aortic Valve Replacement in Patients at Low*  
361 *Surgical Risk*. J Am Coll Cardiol, 2021. **77**(9): p. 1149-1161.
- 362 4. Makkar, R.R., et al., *Five-Year Outcomes of Transcatheter or Surgical Aortic-Valve Replacement*. N Engl  
363 J Med, 2020. **382**(9): p. 799-809.
- 364 5. Popma, J.J., et al., *Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk*  
365 *Patients*. N Engl J Med, 2019. **380**(18): p. 1706-1715.
- 366 6. Moher, D., et al., *Preferred reporting items for systematic reviews and meta-analyses: the PRISMA*  
367 *statement*. PLoS Med, 2009. **6**(7): p. e1000097.
- 368 7. Shahian, D.M., et al., *The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models:*  
369 *Part 1-Background, Design Considerations, and Model Development*. Ann Thorac Surg, 2018. **105**(5): p.  
370 1411-1418.
- 371 8. Capodanno, D., et al., *Standardized definitions of structural deterioration and valve failure in assessing*  
372 *long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement*  
373 *from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the*  
374 *European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery*  
375 *(EACTS)*. Eur J Cardiothorac Surg, 2017. **52**(3): p. 408-417.
- 376 9. Liu, N., Y. Zhou, and J.J. Lee, *IPDfromKM: reconstruct individual patient data from published*  
377 *Kaplan-Meier survival curves*. BMC Med Res Methodol, 2021. **21**(1): p. 111.
- 378 10. Blackman, D.J., et al., *Long-Term Durability of Transcatheter Aortic Valve Prostheses*. J Am Coll Cardiol,  
379 2019. **73**(5): p. 537-545.
- 380 11. Erlebach, M., et al., *The 10-year horizon: Survival and structural valve degeneration in first-generation*  
381 *transcatheter aortic valves*. Arch Cardiovasc Dis, 2022. **115**(6-7): p. 369-376.
- 382 12. McGrath, S., et al., *Estimating the sample mean and standard deviation from commonly reported*  
383 *quantiles in meta-analysis*. Stat Methods Med Res, 2020. **29**(9): p. 2520-2537.
- 384 13. Barbanti, M., et al., *Incidence of Long-Term Structural Valve Dysfunction and Bioprosthetic Valve*  
385 *Failure After Transcatheter Aortic Valve Replacement*. J Am Heart Assoc, 2018. **7**(15): p. e008440.
- 386 14. Brízido, C., et al., *Surgical versus transcatheter aortic valve replacement in low-risk patients: A*  
387 *long-term propensity score-matched analysis*. Catheter Cardiovasc Interv, 2021. **98**(7): p. E1033-e1043.
- 388 15. Durand, E., et al., *Assessment of Long-Term Structural Deterioration of Transcatheter Aortic*  
389 *Bioprosthetic Valves Using the New European Definition*. Circ Cardiovasc Interv, 2019. **12**(4): p.  
390 e007597.
- 391 16. Eltchaninoff, H., et al., *Assessment of structural valve deterioration of transcatheter aortic*  
392 *bioprosthetic balloon-expandable valves using the new European consensus definition*.  
393 EuroIntervention, 2018. **14**(3): p. e264-e271.
- 394 17. Jørgensen, T.H., et al., *Eight-year outcomes for patients with aortic valve stenosis at low surgical risk*  
395 *randomized to transcatheter vs. surgical aortic valve replacement*. Eur Heart J, 2021. **42**(30): p.  
396 2912-2919.
- 397 18. Panico, R.A., et al., *Long-term results and durability of the CoreValve transcatheter aortic*  
398 *bioprosthesis: outcomes beyond five years*. EuroIntervention, 2019. **14**(16): p. 1639-1647.
- 399 19. Sathananthan, J., et al., *Ten year follow-up of high-risk patients treated during the early experience*  
400 *with transcatheter aortic valve replacement*. Catheter Cardiovasc Interv, 2021. **97**(3): p. E431-e437.
- 401 20. Scotti, A., et al., *10-Year Impact of Transcatheter Aortic Valve Replacement Leaflet Design (Intra-*  
402 *Versus Supra-Annular) in Mortality and Hemodynamic Performance*. Front Cardiovasc Med, 2022. **9**: p.

- 403 924958.
- 404 21. Testa, L., et al., *Long-term clinical outcome and performance of transcatheter aortic valve replacement*  
405 *with a self-expandable bioprosthesis*. Eur Heart J, 2020. **41**(20): p. 1876-1886.
- 406 22. Vriesendorp, P.A., et al., *Short- and Long-Term Outcomes After Transcatheter Aortic Valve Implantation*  
407 *in Public and Private Hospital Settings: A Propensity-Matched Analysis*. Heart Lung Circ, 2021. **30**(12):  
408 p. 1910-1917.
- 409 23. Clark, M.A., et al., *Five-year clinical and economic outcomes among patients with medically managed*  
410 *severe aortic stenosis: results from a Medicare claims analysis*. Circ Cardiovasc Qual Outcomes, 2012.  
411 **5**(5): p. 697-704.
- 412 24. Kapadia, S.R., et al., *5-year outcomes of transcatheter aortic valve replacement compared with*  
413 *standard treatment for patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled*  
414 *trial*. Lancet, 2015. **385**(9986): p. 2485-91.
- 415 25. Malvindi, P.G., et al., *Long-term survival after surgical aortic valve replacement in patients aged 80*  
416 *years and over*. Eur J Cardiothorac Surg, 2021. **60**(3): p. 671-678.
- 417 26. Brennan, J.M., et al., *Long-term survival after aortic valve replacement among high-risk elderly*  
418 *patients in the United States: insights from the Society of Thoracic Surgeons Adult Cardiac Surgery*  
419 *Database, 1991 to 2007*. Circulation, 2012. **126**(13): p. 1621-9.
- 420 27. Sá, M., et al., *Surgical aortic valve replacement and patient-prosthesis mismatch: a meta-analysis of*  
421 *108 182 patients*. Eur J Cardiothorac Surg, 2019. **56**(1): p. 44-54.
- 422 28. Sá, M.P., et al., *Impact of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement:*  
423 *Meta-Analysis of Kaplan-Meier-Derived Individual Patient Data*. JACC Cardiovasc Imaging, 2022.
- 424 29. Herrmann, H.C., et al., *Prosthesis-Patient Mismatch in Patients Undergoing Transcatheter Aortic Valve*  
425 *Replacement: From the STS/ACC TVT Registry*. J Am Coll Cardiol, 2018. **72**(22): p. 2701-2711.
- 426 30. Tang, G.H.L., et al., *Outcomes of Prosthesis-Patient Mismatch Following Supra-Annular Transcatheter*  
427 *Aortic Valve Replacement: From the STS/ACC TVT Registry*. JACC Cardiovasc Interv, 2021. **14**(9): p.  
428 964-976.
- 429 31. Généreux, P., et al., *Valve Academic Research Consortium 3: Updated Endpoint Definitions for*  
430 *Aortic Valve Clinical Research*. J Am Coll Cardiol, 2021. **77**(21): p. 2717-2746.
- 431 32. Johnston, D.R., et al., *Long-term durability of bioprosthetic aortic valves: implications from 12,569*  
432 *implants*. Ann Thorac Surg, 2015. **99**(4): p. 1239-47.
- 433 33. Ueyama, H., et al., *Meta-Analysis Comparing Valve Durability Among Different Transcatheter and*  
434 *Surgical Aortic Valve Bioprosthesis*. Am J Cardiol, 2021. **158**: p. 104-111.
- 435 34. Bavaria, J.E., et al., *Five-year Outcomes of the COMMENCE Trial Investigating Aortic Valve*  
436 *Replacement with RESILIA Tissue*. Ann Thorac Surg, 2022.
- 437 35. Deutsch, M.A., et al., *Beyond the five-year horizon: long-term outcome of high-risk and inoperable*  
438 *patients undergoing TAVR with first-generation devices*. EuroIntervention, 2018. **14**(1): p. 41-49.
- 439

440

441

442

443

444

445

446

447



448

449

450 **Figure Legend**

451 Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)

452 flow diagram.

453 Figure 2. Kaplan-Meier curve describing overall survival following TAVR with 95%

454 confidence intervals reconstructed from pooled individual patient data. TAVR: transcatheter

455 aortic valve replacement.

456 A: overall cohort

457 B: cohort excluding patients with low surgical risk

458 Figure 3. Kaplan-Meier curve describing freedom from SVD following TAVR with 95%

459 confidence intervals reconstructed from pooled individual patient data. SVD: structural valve

460 deterioration; TAVR: transcatheter aortic valve replacement.

461 A: overall cohort

462 B: cohort excluding patients with low surgical risk

463

464

465

**Table 1. Summary of included studies and patient characteristics**

Author	N of patients	Country	Design	Study Period	Median follow-up period, years	Age	Male	NYHA III-IV	Diabetes	Hypertension	PVD	COPD	Renal failure	Prior MI	Prior AF	Prior stroke	Prior pacemaker	Prior PCI	Prior CABG	Prior Cardiac Surgery	STS score, %	LVEF, %
Elтчаниnoff et al, 2018	378	France	Prospective Cohort	April 2002 to September 2012	3.1 (0.9-5.0)	83.3±6.8	177 (45.9)	290 (75.1)	83 (21.5)	216 (56.0)	304 (80.4)	NA	289 (74.9)	91 (23.6)	148 (38.3)	23 (6.0)	48 (12.4)	105 (27.2)	71 (18.4)	NA	10.6±8.5	55.0±16.3
Barbanti et al, 2018	287	Italy	Prospective Cohort	June 4, 2007 to March 30, 2012	6.7	80.7±5.3	120 (41.7)	195 (67.7)	76 (26.4)	248 (86.1)	17 (5.9)	102 (35.4)	59 (20.5)	53 (18.4)	44 (15.3)	18 (6.3)	28 (9.7)	88 (30.6)	31 (10.8)	NA	8.1±5.1	53.3±15.9
Panico et al, 2019	278	Italy	Prospective Cohort	September 2007 to July 2013	6.8	82.3±5.5	132 (47.5)	NA	84 (30.2)	234 (84.2)	82 (29.5)	46 (16.55)	NA	40 (14.4)	NA	NA	NA	NA	NA	NA	6.4±5.0	NA
Durand et al, 2019	1264	France	Prospective Cohort	April 2002 to December 2011	3.9 (1.9-5.1)	82.6±7.5	651 (51.8)	1013 (83.0)	301 (24.0)	859 (68.5)	333 (26.6)	NA	867 (71.1)	238 (18.9)	377 (32.4)	117 (9.3)	181 (14.9)	NA	235 (22.7)	NA	NA	52.8±14.4
Testa et al, 2020	990	Italy	Prospective Cohort	June 2007 to December 2011	4.4 (1.5-6.7)	82±6	450 (45.5)	733 (74.0)	266 (26.9)	805 (81.3)	NA	256 (25.9)	220 (22.2)	187 (18.9)	NA	157 (15.9)	NA	296 (29.9)	143 (14.4)	NA	9±10	51±12
Sathanathan et al, 2020	235	Canada	Retrospective Cohort	2005 to 2009	NA	82.4±7.9	118 (50.2)	NA	59 (25.1)	165 (70.2)	75 (31.9)	62 (26.4)	129 (54.9)	127 (54.0)	104 (44.3)	44 (18.7)	38 (16.2)	NA	NA	86 (36.6)	NA	NA
Vriesendorp et al, 2021 (public)	344	Australia	Prospective Cohort	August 2008 to July 2019	3.3 (2.2-5.0)	83.8±5.5	278 (44.8)	NA	154 (30.4)	365 (72.0)	71 (14.0)	115 (22.7)	36 (7.1)	NA	178 (35.1)	81 (16.0)	NA	NA	NA	110 (21.7)	4.6±3.4	NA
Vriesendorp et al, 2021 (private)	344	Australia	Prospective Cohort	August 2008 to July 2019	2.8 (1.5-4.7)	83.6±5.6	224 (51.4)	NA	96 (22.0)	283 (64.9)	96 (22.0)	39 (8.2)	37 (8.5)	NA	117 (26.8)	50 (11.4)	NA	NA	NA	102 (23.4)	5.0±3.1	NA
Brizido et al, 2021	79	Portugal	Retrospective Cohort	June 2009 to July 2017	NA	81±8	39 (49)	38 (48.1)	25 (32)	35 (44)	NA	14 (18)	18 (23)	NA	16 (20)	9 (11)	NA	NA	NA	NA	NA	NA
Jørgensen et al, 2021	145	Denmark, Sweden	Prospective Cohort	December 2009 to December 2012	NA	79.2±4.9	78 (53.8)	70 (48.6)	26 (17.9)	103 (71.0)	6 (4.1)	17 (11.7)	NA	8 (5.5)	40 (27.8)	24 (16.6)	5 (3.4)	11 (7.6)	NA	NA	2.9±1.6	NA
Erlebach et al, 2022	510	Germany	Prospective Cohort	June 2007 to December 2010	4.6±3.3	79.6±6.7	193 (37.8)	NA	131 (25.7)	404 (79.2)	NA	92 (18.1)	NA	NA	NA	72 (14.2)	39 (7.6)	NA	NA	128 (25)	6.0±3.1	NA
Scotti et al, 2022	604	Italy	Prospective Cohort	June 2007 to December 2016	4.9 (2.5-6.2)	82 (78, 85)	283 (46.9)	339 (56)	175 (29)	543 (91)	NA	151 (25)	295 (49)	111 (18)	195 (33)	78 (13)	51 (8)	198 (33)	75 (12)	93 (15)	4.8 (3.1, 10.2)	55±15
Blackman et al, 2019	241	United Kingdom	Prospective Cohort	2007 to 2011	5.8 (5.3-7.7)	79.3±7.5	126 (54.0)	NA	52 (23.3)	NA	60 (26.0)	60 (26.9)	NA	60 (25.6)	54 (25.0)	43 (19.3)	NA	NA	NA	92 (41.3)	NA	NA

468

469 Values are n (%), mean  $\pm$  SD, or median (range)

470 NYHA: New York Heart Association; PVD: peripheral vascular disease; COPD: chronic pulmonary disease; HF: heart failure; MI: myocardial infarction; AF:

471 atrial fibrillation; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; STS: The Society of Thoracic Surgeons; LVEF: left

472 ventricular ejection fraction; NA: not applicable.

473

474

475 **Table 2. Procedural data**

Author	Year	PVT/Cribier-Edwards	SAPIEN	SAPIEN XT	SAPIEN family	CoreValve	Evolut R or family	Jena	Portico	Lotus	Acute	Balloon-expandable	Self-expandable	23 mm	26 mm	29 mm	≥ 26 mm	Valve in valve	New pacemaker
Eltchaninoff <i>et al</i>	2018	73 (20.5)	83 (21.5)	216 (56.0)	299 (77.5)	0	0	0	0	0	0	378 (100)	0	207 (53.6)	167 (43.3)	4 (1.0)	171 (44.3)	0	21 (5.6)
Barbanti <i>et al</i>	2018	NA	NA	48 (16.7)	48 (16.7)	238 (82.6)	0	0	0	0	0	48 (16.7)	238 (82.6)	31 (10.8)	149 (51.7)	95 (33.0)	244 (84.7)	0	47 (16.3)
Panico <i>et al</i>	2019	0	0	0	0	278 (100)	0	0	0	0	0	0	278 (100)	NA	NA	NA	NA	0	98 (35.3)
Durand <i>et al</i>	2019	70 (5.5)	475 (37.6)	512 (40.5)	987 (78.1)	199 (15.7)	0	7 (0.6)	0	0	0	1057 (83.6)	206 (16.3)	471 (37.7)	NA	NA	779 (62.3)	0	147 (14.9)
Testa <i>et al</i>	2020	0	0	0	0	990 (100)	NA	0	0	0	0	0	990 (100)	NA	257 (54.2)	439 (44.3)	711 (100)	0	NA
Sathananthan <i>et al</i>	2020	49 (20.9)	182 (77.4)	0	182 (77.4)	4 (1.7)	0	0	0	0	0	231 (98.3)	4 (1.7)	58 (24.7)	174 (74.0)	3 (1.3)	177 (75.3)	5 (2.1)	NA
Vriesendorp <i>et al</i> (public)	2021	NA	NA	NA	NA	NA	NA	NA	0	0	0	150 (29.6)	36 (8.3)	NA	NA	NA	NA	0	59 (17.2)
Vriesendorp <i>et al</i> (private)	2021	NA	NA	NA	NA	NA	NA	NA	0	0	0	357 (70.4)	400 (91.7)	NA	NA	NA	NA	0	71 (20.6)
Brizido <i>et al</i>	2021	NA	NA	NA	28 (35.4)	NA	41 (51.9)	0	8 (10.1)	2 (3)	0	28 (35)	49 (62)	NA	NA	NA	NA	0	15 (19)
Jørgensen <i>et al</i>	2021	0	0	0	0	142 (100)	0	0	0	0	0	0	142 (100)	2 (1.4)	57 (40.1)	69 (48.6)	140 (98.6)	0	42.5 (11.0)
Erlebach <i>et al</i>	2022	NA	147 (28.9)	14 (2.7)	161 (31.2)	348 (68.2)	NA	NA	NA	NA	0	161 (31.2)	348 (68.2)	58 (11.4)	236 (46.4)	215 (42.2)	451 (88.6)	0	101 (19.8)
Scotti <i>et al</i>	2022	0	NA	230 (38.1)	425 (70.4)	99 (16.4)	0	0	0	57 (9.4)	23 (3.8)	425 (70.4)	179 (29.6)	192 (31.8)	249 (41.2)	65 (10.8)	384 (63.6)	0	NA
Blackman <i>et al</i>	2019	0	45 (19.3)	35 (15.0)	80 (34.3)	149 (64.0)	0	0	4 (1.7)	0	0	80 (33.2)	153 (63.5)	NA	NA	NA	NA	16 (6.8)	39 (17.6)

476

477 Values are n (%).

478 PVT: Percutaneous Valve Technologies, NA: not applicable.


479

480


481


482

483




Survival probability








Freedom from SVD



Freedom from SVD



1364

962

726

461

149